Xiaobin Lv

617 total citations
11 papers, 456 citations indexed

About

Xiaobin Lv is a scholar working on Molecular Biology, Cancer Research and Oncology. According to data from OpenAlex, Xiaobin Lv has authored 11 papers receiving a total of 456 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 4 papers in Cancer Research and 3 papers in Oncology. Recurrent topics in Xiaobin Lv's work include RNA modifications and cancer (4 papers), Cancer, Hypoxia, and Metabolism (2 papers) and Ubiquitin and proteasome pathways (2 papers). Xiaobin Lv is often cited by papers focused on RNA modifications and cancer (4 papers), Cancer, Hypoxia, and Metabolism (2 papers) and Ubiquitin and proteasome pathways (2 papers). Xiaobin Lv collaborates with scholars based in China and United States. Xiaobin Lv's co-authors include Yi Sang, Lei Zeng, Chun Cheng, Jianjun Tang, Yanqing Wu, Yinghua Zhu, Qiannan Guo, Junjun Chu, Kaishun Hu and Lijuan Liu and has published in prestigious journals such as Cancer Research, Oncogene and Scientific Reports.

In The Last Decade

Xiaobin Lv

10 papers receiving 451 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Xiaobin Lv China 10 363 237 61 42 29 11 456
Shentong Yu China 8 452 1.2× 342 1.4× 73 1.2× 22 0.5× 40 1.4× 11 524
Wenzhi Li China 15 300 0.8× 274 1.2× 41 0.7× 59 1.4× 37 1.3× 27 492
Zhiwei Chen China 11 294 0.8× 128 0.5× 110 1.8× 41 1.0× 38 1.3× 24 404
Qiongying Lv China 10 198 0.5× 123 0.5× 57 0.9× 56 1.3× 39 1.3× 11 316
Jun Zou China 9 301 0.8× 159 0.7× 84 1.4× 54 1.3× 34 1.2× 15 393
Shyamananda Singh Mayengbam India 7 181 0.5× 200 0.8× 61 1.0× 29 0.7× 33 1.1× 8 331
Yannasittha Jiramongkol United Kingdom 8 261 0.7× 99 0.4× 59 1.0× 26 0.6× 52 1.8× 12 373

Countries citing papers authored by Xiaobin Lv

Since Specialization
Citations

This map shows the geographic impact of Xiaobin Lv's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiaobin Lv with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiaobin Lv more than expected).

Fields of papers citing papers by Xiaobin Lv

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xiaobin Lv. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiaobin Lv. The network helps show where Xiaobin Lv may publish in the future.

Co-authorship network of co-authors of Xiaobin Lv

This figure shows the co-authorship network connecting the top 25 collaborators of Xiaobin Lv. A scholar is included among the top collaborators of Xiaobin Lv based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xiaobin Lv. Xiaobin Lv is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

11 of 11 papers shown
1.
Lv, Xiaobin, Ying Yu, Zhuowei Chen, et al.. (2025). Molecular engineering development of β-galactosidase-activatable fluorogenic probes for precise senescence tracking in cells, tissues and a mouse model of psoriasis. Sensors and Actuators B Chemical. 444. 138406–138406.
2.
Ma, Cong, Jiayu Li, Junhong Li, et al.. (2023). Indirect bilirubin impairs invasion of osteosarcoma cells via inhibiting the PI3K/AKT/MMP-2 signaling pathway by suppressing intracellular ROS. Journal of bone oncology. 39. 100472–100472. 11 indexed citations
3.
Yu, Bo, Lang Liu, Feng Cai, et al.. (2022). The synergistic anticancer effect of the bromodomain inhibitor OTX015 and histone deacetylase 6 inhibitor WT-161 in osteosarcoma. Cancer Cell International. 22(1). 64–64. 13 indexed citations
4.
Fan, Song, Tian Tian, Weixiong Chen, et al.. (2019). Mitochondrial miRNA Determines Chemoresistance by Reprogramming Metabolism and Regulating Mitochondrial Transcription. Cancer Research. 79(6). 1069–1084. 116 indexed citations
5.
Yang, Su, Yan Zhou, Yuanjue Sun, et al.. (2018). Macrophage-derived CCL18 promotes osteosarcoma proliferation and migration by upregulating the expression of UCA1. Journal of Molecular Medicine. 97(1). 49–61. 41 indexed citations
6.
Wu, Yanqing, Yinghua Zhu, Shunrong Li, et al.. (2017). Terrein performs antitumor functions on esophageal cancer cells by inhibiting cell proliferation and synergistic interaction with cisplatin. Oncology Letters. 13(4). 2805–2810. 15 indexed citations
7.
Tang, Xiaofeng, Jianjun Tang, Xia Liu, et al.. (2016). Downregulation of miR-129-2 by promoter hypermethylation regulates breast cancer cell proliferation and apoptosis. Oncology Reports. 35(5). 2963–2969. 46 indexed citations
8.
Lv, Xiaobin, Lijuan Liu, Chun Cheng, et al.. (2015). SUN2 exerts tumor suppressor functions by suppressing the Warburg effect in lung cancer. Scientific Reports. 5(1). 17940–17940. 72 indexed citations
9.
Chu, Junjun, Yanqing Wu, Lijuan Sun, et al.. (2015). NBAT1 suppresses breast cancer metastasis by regulating DKK1 via PRC2. Oncotarget. 6(32). 32410–32425. 78 indexed citations
10.
Lv, Xiaobin, Wei Wu, Xiaofeng Tang, et al.. (2015). Regulation of SOX10 stability via ubiquitination-mediated degradation by Fbxw7α modulates melanoma cell migration. Oncotarget. 6(34). 36370–36382. 19 indexed citations
11.
Xu, Shihe, Zizhen Feng, Yi Sang, et al.. (2011). hSSB1 binds and protects p21 from ubiquitin-mediated degradation and positively correlates with p21 in human hepatocellular carcinomas. Oncogene. 30(19). 2219–2229. 45 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Shentong Yu Breakdown of academic impact, for papers by Wenzhi Li Breakdown of academic impact, for papers by Zhiwei Chen Breakdown of academic impact, for papers by Qiongying Lv Breakdown of academic impact, for papers by Jun Zou Breakdown of academic impact, for papers by Shyamananda Singh Mayengbam Breakdown of academic impact, for papers by Yannasittha Jiramongkol
Rankless by CCL
2026